Janney Capital analyst Ken Trbovich said in a note titled "FDA embarrasses ACOR with RTF for Inbrija" that the industry has submitted 509 NDAs or BLAs in fiscal years 2013-2016 and just 5 "refusal to file" letters have been issued, leaving Acorda Therapeutics "the ignominy of being among the less than 1% to receive an RTF." He has pushed out his view of the drug's expected launch to the first half of 2019 from the first half of next year, but he has also raised his pricing assumptions for Inbrija, leaving his fair value estimate for Acorda unchanged at $18. Trbovich, who also thinks the delay may allow Sunovion's competing Parkinson's OFF rescue program to catch up, keeps a Neutral rating on Acorda shares.